2022 AMI Online Salon

Asparaginase in Treatment of T-Cell Acute Lymphoblastic Leukemia (ALL)

Project Detail

  • Entrant Name:  Hoc Kho
  • Client: Servier Pharmaceuticals
  • Copyright: Servier Pharmaceuticals, 2022
  • Medium/software used: Cinema 4D, Redshift, After Effects, Premier Pro
  • Final presentation format: Animation
  • Primary Audience: Healthcare Providers

Project Description

T-cell acute lymphoblastic leukemia is an aggressive subtype of acute lymphoblastic leukemia (ALL), a type of cancer wherein bone marrow creates a surplus of immature lymphocytes. Leukemic cells that have metastasized to the central nervous system (CNS) are protected from standard forms of chemotherapy, thus increasing the risk for CNS recurrence and relapsed disease. This animation elucidates the goal of sustained asparaginase therapy, which is to deplete leukemic T-cells by targeting their source of growth, asparagine. Asparaginase therapy decreases levels of extracellular asparagine, resulting in leukemic cell apoptosis throughout the body, including the CNS. The purpose of this animation is to market the therapeutic’s unique mechanism of action to healthcare providers.A prominent goal of this animation is to represent a diverse patient population in age, race, and gender. Toward that end, “patient mosaic” visuals at the beginning and end of the animation focus on the demographic this disease impacts. While T-cell ALL is more common in younger patients, who have a higher chance of remission, there are also some cases in older adults. To optimize legibility, all labels are in a larger font with contrasting backgrounds.